Condensed Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Total	Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning Balance at Dec. 31, 2023	$ 3,580			$ 41,466	$ (37,886)
Beginning Balance (Shares) at Dec. 31, 2023			86,241
Issuance of common stock for restricted stock award (in shares)			441
Stock-based compensation expense	54			54
Net loss	(1,481)				(1,481)
Ending Balance at Mar. 31, 2024	2,153			41,520	(39,367)
Ending Balance (Shares) at Mar. 31, 2024			86,682
Beginning Balance at Dec. 31, 2024	2,535		$ 1	46,075	(43,541)
Beginning Balance (Shares) at Dec. 31, 2024			556,902
Issuance of stock for consideration of licensed technology	1,700			1,700
Issuance of stock for consideration of licensed technology (Shares)		491	111,339
Issuance of common stock for equity line of credit	94			94
Issuance of common stock for equity line of credit (Shares)			29,800
Issuance of common stock in lieu of fractional shares for stock split (In shares)			76
Exercise of warrants	109			109
Exercise of warrants (Shares)			7,524
Stock-based compensation expense	100			100
Net loss	(1,502)				(1,502)
Ending Balance at Mar. 31, 2025	$ 3,036		$ 1	$ 48,078	$ (45,043)
Ending Balance (Shares) at Mar. 31, 2025		491	705,641